{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:15:54Z","timestamp":1778192154057,"version":"3.51.4"},"reference-count":67,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,8,8]],"date-time":"2008-08-08T00:00:00Z","timestamp":1218153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Occult hepatitis B virus (HBV) infection is characterized by undetectable serum HBV surface antigen (HBsAg) but detectable HBV\u2010DNA in serum or liver.<\/jats:p><jats:p><jats:bold>Aims: <\/jats:bold> To determine the prevalence and clinical impact of occult HBV in autoimmune liver diseases as similar data are missing.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> One hundred and ninety\u2010six sera samples from HBsAg\u2010negative patients, including 66 autoimmune hepatitis (AIH), 93 primary biliary cirrhosis (PBC) and 37 primary sclerosing cholangitis (PSC), were investigated for HBV\u2010DNA using the polymerase chain reaction (PCR) before treatment initiation. One hundred and three serial samples from 38 AIH patients under immunosuppression and 282 selected blood donors (HBsAg negative; antibodies to HBV\u2010core antigen positive) were also investigated. Fourteen available paraffin\u2010embedded AIH liver samples were also investigated for HBV\u2010DNA by nested\u2010PCR.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Hepatitis B virus DNA was detected in the serum of 24\/196 patients (12.2%) and 0\/282 donors (<jats:italic>P<\/jats:italic>=0.0000). Nine patients had AIH (13.6%), eight had PBC (8.6%) and seven had PSC (18.9%) (<jats:italic>P<\/jats:italic>=0.0000 vs healthy). HBV\u2010DNA detection in AIH livers was higher than in serum. HBV\u2010DNA was associated neither with HBV markers nor with epidemiological, laboratory and clinical data. Serial testing of AIH patients revealed two HBV\u2010DNA\u2010negative patients before treatment becoming positive during treatment, while all HBV\u2010DNA\u2010positive patients before immunosuppression became negative.<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> Based mainly on serum HBV\u2010DNA, we found a significant proportion of autoimmune liver disease patients with occult HBV compared with donors. However, taking into account our results in a small number of liver tissues, it should be emphasized that occult HBV could be even higher when both serum and liver specimens are investigated. Occult HBV does not seem to affect the clinical and laboratory features of the diseases, while AIH patients with occult HBV under immunosuppression do not deteriorate during follow\u2010up.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2008.01851.x","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T11:05:30Z","timestamp":1233745530000},"page":"434-442","source":"Crossref","is-referenced-by-count":44,"title":["Occult hepatitis B virus infection in patients with autoimmune liver diseases"],"prefix":"10.1111","volume":"29","author":[{"given":"Sarah P.","family":"Georgiadou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Zachou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Liaskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Gabeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini I.","family":"Rigopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,4]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"World Health Organization; Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2004). WHO Web site 2000.http:\/\/who.int\/inf\u2010fs\/en\/fact204.html."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200205303462202"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712113372406"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190304"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1995.35195090661.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50171"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00083-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00344.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80005-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00345-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00513.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80311-6"},{"key":"e_1_2_6_14_2","first-page":"201","article-title":"Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus\u2010associated chronic liver disease","volume":"58","author":"Fukuda R","year":"1999","journal-title":"clinical and virological significance"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907013410104"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199804)54:4<249::AID-JMV3>3.0.CO;2-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200103)63:3<220::AID-JMV1004>3.0.CO;2-3"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02063934"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.07.003"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000025030"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(03)00117-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03439.x"},{"key":"e_1_2_6_23_2","first-page":"350","article-title":"HCV genotype and \u201csilent\u201d HBV coinfection","volume":"64","author":"Sagnelli E","year":"2001","journal-title":"two main risk factors for a more severe liver disease"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.11.4068-4071.2002"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.10.007"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199704)51:4<313::AID-JMV9>3.0.CO;2-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.1096.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.10.016"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2003.01742.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(00)02164-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.284"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21702"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702093"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21051"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.8.706"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050408"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21059"},{"key":"e_1_2_6_38_2","first-page":"293","article-title":"Autoantibodies and defined target autoantigens in autoimmune hepatitis","volume":"13","author":"Dalekos GN","year":"2002","journal-title":"an overview"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2002.017410.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(03)00030-2"},{"key":"e_1_2_6_41_2","first-page":"929","article-title":"International autoimmune hepatitis group report","volume":"31","author":"Alvarez F","year":"1999","journal-title":"review of criteria for diagnosis of autoimmune hepatitis"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036558"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.01.002"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.023"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.009"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.01.016"},{"key":"e_1_2_6_47_2","article-title":"Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece","author":"Stefos A","year":"2008","journal-title":"Eur J Intern Med"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)00100-8"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.429"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05706.x"},{"key":"e_1_2_6_51_2","first-page":"173","article-title":"Impact of HBV, HCV and GB\u2010GHGV on hepatocellular carcinoma in Europe","volume":"29","author":"Brechot C","year":"1998","journal-title":"results of a European concerted action"},{"key":"e_1_2_6_52_2","first-page":"20","article-title":"Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg\u2010negative patients","volume":"17","author":"Paterlini P","year":"1993","journal-title":"a study of a low-endemic area"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01730369"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21529"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.048"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000232232.41877.2a"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1104"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118902"},{"key":"e_1_2_6_59_2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1074\/jbc.M204241200","article-title":"Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein","volume":"27","author":"Chen SY","year":"2003","journal-title":"J Biol Chem"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00296-9"},{"key":"e_1_2_6_61_2","first-page":"438","article-title":"Time\u2010dependent events in natural history of occult hepatitis B virus infection","volume":"42","author":"Chen CJ.","year":"2005","journal-title":"the importance of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements"},{"key":"e_1_2_6_62_2","first-page":"299","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"62","author":"Yeo W","year":"2000","journal-title":"a prospective study of 626 patients with identification of risk factors"},{"key":"e_1_2_6_63_2","first-page":"983","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases","volume":"65","author":"Calabrese LH","year":"2006","journal-title":"assessment and preventive strategies"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601699"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200608000-00021"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026642517735"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537282"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2060"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2008.01851.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2008.01851.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T19:14:20Z","timestamp":1697138060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2008.01851.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,4]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1478-3231.2008.01851.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01851.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,4]]}}}